Recipharm CEO anticipates 2024 will be ‘as hard’ for CDMOs, strategy will be key for endurance

Re­ci­pharm CEO Marc Funk an­tic­i­pates 2024 to be just as chal­leng­ing for CD­MOs in terms of find­ing op­por­tu­ni­ties for growth due to wider eco­nom­ic chal­lenges.

“Next year is go­ing to be, with re­gret, equal­ly as hard,” Funk told End­points News in an in­ter­view. “If your [prof­it] mar­gin is eat­en by in­fla­tion or ma­te­r­i­al costs in­crease, it’s dif­fi­cult to make the right prof­itabil­i­ty to have enough mon­ey to do in­vest­ments, and this is a bat­tle that we have to fight,” he added.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.